19:25 , Oct 11, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Cryptosporidium Cell culture and mouse studies identified two compounds that could help treat Cryptosporidium infections. Screening of 12,000 approved or investigational compounds in a C. parvum-infected human cell line identified two compounds, VB-201 and ASP7962,...
17:33 , Aug 3, 2018 |  BC Week In Review  |  Clinical News

Lilly's mirikizumab improves clinical remission in Phase II for ulcerative colitis

Eli Lilly and Co. (NYSE:LLY) reported in June that 200 mg IV mirikizumab (LY3074828) met the primary endpoint of improving clinical remission rate at week 12 vs. placebo in a Phase II trial to treat...
17:06 , Aug 3, 2018 |  BC Week In Review  |  Clinical News

CHMP positive on patisiran, Symkevi, Humira and Neulasta biosimilars

EMA's CHMP recommended a number of approvals July 26, including Onpattro patisiran from Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), Symkevi tezacaftor/ivacaftor from Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), a handful of cancer therapies and three biosimilars. The committee recommended approval...
22:08 , Jul 27, 2018 |  BC Extra  |  Company News

CHMP positive on patisiran, Symkevi, Humira and Neulasta biosimilars

EMA's CHMP recommended a number of approvals Friday, including Onpattro patisiran from Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), Symkevi tezacaftor/ivacaftor from Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), a handful of cancer therapies and three biosimilars. The committee recommended approval of...
22:53 , Jul 12, 2018 |  BC Extra  |  Politics & Policy

ICER panel votes against elagolix for endometriosis

An ICER panel showed little confidence in the clinical effectiveness of elagolix (ABT-620) from AbbVie Inc. (NYSE:ABBV) to treat endometriosis, voting Thursday that evidence is not adequate to support a net health benefit over other...
19:42 , May 18, 2018 |  BC Week In Review  |  Clinical News

Novartis to start head-to-head trial of Cosentyx and Tremfya

Novartis AG (NYSE:NVS; SIX:NOVN) plans to begin the head-to-head Phase IIa ARROW trial to compare Cosentyx secukinumab to Tremfya guselkumab for 16 weeks in 40 patients with Stelara ustekinumab-resistant plaque psoriasis. The pharma expects to...
20:58 , Apr 6, 2018 |  BC Week In Review  |  Clinical News

Oxford BioDynamics reports data for predicting inadequate responders to methotrexate

Oxford BioDynamics plc (LSE:OBD) and colleagues reported that the presence of a five-marker Chromosome Confirmation Signature (CCS) in the blood of patients with early rheumatoid arthritis as detected by the company's EpiSwitch epigenetic biomarker platform...
17:56 , Mar 30, 2018 |  BC Week In Review  |  Clinical News

Protagonist discontinues Phase IIb of PTG-100 for UC

Protagonist Therapeutics Inc. (NASDAQ:PTGX) discontinued the Phase IIb PROPEL trial of once-daily PTG-100 to treat moderate to severe ulcerative colitis. Protagonist said it will decide whether to start a Phase II/III trial of the candidate...
18:13 , Mar 26, 2018 |  BC Extra  |  Clinical News

Protagonist shares halved on UC failure

Protagonist Therapeutics Inc. (NASDAQ:PTGX) was down $11.68 (57%) to $8.75 on Monday after the company discontinued the Phase IIb PROPEL trial of PTG-100 to treat moderate to severe ulcerative colitis. Protagonist said it will decide...
18:29 , Mar 23, 2018 |  BC Week In Review  |  Clinical News

Sun's IL-23 psoriasis mab approved by FDA

Sun Pharmaceutical Industries Ltd. (BSE:524715; NSE:SUNPHARMA) said FDA approved Ilumya tildrakizumab-asmn (MK-3222) to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Ilumya is a humanized mAb against IL-23 subunit alpha...